Boston Biomedical: Focused on Innovative Cancer Research
Boston Biomedical is committed to developing innovative next-generation cancer therapeutics. Our most advanced research program involves inhibitors of cancer stem cell (CSC) pathways. In addition, we have several other research approaches targeting cancer stem cell pathways, including peptide vaccines and immune response modifiers, which are in preclinical and early clinical development.
Cancer Stem Cell Research Program
Clinically advanced research efforts at Boston Biomedical involve the use of various proprietary platform technologies to identify and develop therapeutics that target CSC pathways. These technologies allow for the efficient discovery of and research into anti-CSC pathway therapeutics. This is in contrast with conventional drug discovery approaches, which rely on an inefficient, quantity-driven paradigm that employs high-throughput technology in an attempt to manage the biological and chemical complexity required to bring new drugs to market.
The approach used by the Boston Biomedical team has proven to be productive for discovering innovative drug candidates for further study. Currently, Boston Biomedical’s most advanced investigational agents are napabucasin and amcasertib (BBI-503), which are being studied across all phases of clinical development and in multiple tumor types.